Ticagrelor + Aspirin + Rivaroxaban + Aspirin + Clopidogrel + Aspirin
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intracranial Arteriosclerosis
Conditions
Intracranial Arteriosclerosis, Stroke
Trial Timeline
Aug 2, 2022 → May 31, 2028
NCT ID
NCT05047172About Ticagrelor + Aspirin + Rivaroxaban + Aspirin + Clopidogrel + Aspirin
Ticagrelor + Aspirin + Rivaroxaban + Aspirin + Clopidogrel + Aspirin is a phase 3 stage product being developed by AstraZeneca for Intracranial Arteriosclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05047172. Target conditions include Intracranial Arteriosclerosis, Stroke.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05047172 | Phase 3 | Active |
Competing Products
6 competing products in Intracranial Arteriosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tirzepatide + Tirzepatide Placebo | Eli Lilly | Approved | 85 |
| cabazitaxel + lapatinib | Novartis | Phase 2 | 52 |
| Everolimus + Bevacizumab | Novartis | Phase 2 | 52 |
| [177Lu]Lu-DOTATATE | Novartis | Phase 2 | 52 |
| Methylprednisolone (Injectable Form) + Placebo Injection | Brain Biotech | Approved | 77 |
| Vismodegib + FAK Inhibitor GSK2256098 + Capivasertib + Abemaciclib | Brain Biotech | Phase 2 | 44 |